

Status: For immediate distribution

Date: 19th July 2007

MEDIA RELEASE

“A major breakthrough for infection control”

19th July 2007, London, UK. At a time when pathogenic bacteria or ‘superbugs’ such as MRSA and *Clostridium difficile* are rapidly becoming resistant to more and more antibiotics, there has been a major infection control development. A group of new copper-based compounds have been proven to be effective against a wide range of hospital acquired infections, as reported in the July 2007 issue of the Journal of Antimicrobial Chemotherapy (JAC).

“I have been an NHS biomedical scientist for forty one years” said Professor Michael Wren MBE, of University College Hospital, London (UCLH). He added, “These are the first truly novel and new antimicrobials compounds that I have seen; they are effective against gram negative, gram positive and anaerobic bacteria such as *Clostridium difficile*.” Professor Wren has conducted comprehensive tests of these highly charged cationic copper electrolytes over the last two years at UCLH under the direction of Dr Vanya Gant, Medical Director for Pathology at UCLH. According to Dr Gant, “These novel copper compounds are exciting because they are effective against a wide range of bacteria and safer than current disinfectants such as chlorine, triclosan and polyquats. Antimicrobial compounds must not only control bacteria, they must also work in the complex hospital environment.”

The powerful antibacterial activity of the novel highly charged cationic copper electrolytes described in the JAC paper has been developed and patented by Remedy Research Limited (Remedy). Remedy is a small pharmaceutical and technology development powerhouse based in London. Remedy’s copper antimicrobials are a platform technology that can be applied to a wide range of applications such as



topical over-the-counter medicines, environmental mitigation, ethical drugs and food safety.

Remedy has licensed the antimicrobial copper compounds to ICICS (Ionx Complete Infection Control Systems) plc for the hospital hygiene and food safety sectors. ICICS will be making available an interactive range of infection control products such as antimicrobial hand gels, hand soaps, surface cleaners and laundry additives, using this breakthrough technology

- ENDS -

Notes for editors

For media enquiries please contact:

Claire Elbrow

Blue Lizard Marketing

+44 (0) 1638 731513

+44 (0) 779 958 8285

info@bluelizardmarketing.com

About Remedy Research

Remedy Research Ltd is a London-based small pharmaceutical and technology development company, founded in 1999 by Spaulding Hickok and Rupert C. Harris.

The Company's primary focus has been research into the microbiocidal properties of three highly charged copper-based inorganic compounds. Over the last two years, the Company has allowed the Clinical Department of Microbiology at the University College NHS Foundation Trust to research and assess the properties of the patented novel biocide compounds.

Remedy Research Ltd developed and patented the compounds covered by the paper in the Journal of Antimicrobial Chemotherapy. The technology has been licensed on a global basis for the duration of the patent to ICICS plc for focused commercial exploitation in the healthcare and food industries.